AUROPHARMA Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > auropharma

Technical Analysis

Technical Strength: 7.1 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 66.9. According to RSI analysis, auropharma is technically strong. 9.0 AUROPHARMA RSI Chart
MACD (?) MACD: 41.5 and Signal Line: 43.9. According to MACD analysis, auropharma is marginally weak. 3.0 AUROPHARMA MACD Chart
Simple Moving Average (?) According to simple moving average analysis, auropharma is in a strong uptrend. Major support levels are 689.9175, 564.841, 520.5628. 10.0 AUROPHARMA Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, auropharma is in a strong uptrend. Major support levels are 686.5813, 612.8924, 554.8888. 10.0 AUROPHARMA Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.829. According to bollinger bands, auropharma is technically strong. 7.0 AUROPHARMA Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 595.6556 and 545.6. Resistance level is 757.7. 6.5 AUROPHARMA Fibonacci Retracement Chart
Average True Range (?) ATR: 32.1 NA AUROPHARMA Average True Range Chart
Average Directional Index (?) ADX is 48.6 which means AUROPHARMA is in a trend. NA AUROPHARMA Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
June 02, 2020
Open Price 729.0
High Price 757.7
Low Price 725.35
Close Price 733.2
Absolute Change 7.55
Percentage Change 1.04%
Weekly Change 2.55%
Monthly Change 12.2%
Yearly Change 10.3%
52-week high 757.7
52-week low 288.85
Corporate Actions
ExDate Purpose
February 17, 2020 INT DIV-RS 1.75 PER SH
November 21, 2019 INT DIV-RS 1.25 PER SH
August 21, 2019 ANNUAL GENERAL MEETING
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)1.1
Confidence in Beta3.07%
Market Capital Rs. 42819.0 Cr
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 02 June 2020: Deliverable Quantity:1.57e+06 NA AUROPHARMA Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 02 June 2020: Daily Volatility:0.768 NA AUROPHARMA Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 02 June 2020: PCR_OI:0.642 PCR:0.534 NA AUROPHARMA PCR Chart
Option Pain (?) 02 June 2020: Max Pain:720.0 NA AUROPHARMA Option Pain Chart
Premium (?) 02 June 2020 Premium: 2.15 Futures OI:11276000.0 NA AUROPHARMA Premium Chart
Option_MAX_OI (?) 02 June 2020: Price:733.2 Put with maximum OI:660.0 Call with maximum OI:800.0 NA AUROPHARMA Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
June 25, 2020 735.35 11276000.0 8778.0 8778.0 733.2
July 30, 2020 738.4 71500.0 77.0 77.0 733.2
August 27, 2020 722.75 0.0 0.0 0.0 733.2

Announcements

June 27, 2019 Related Party Transactions Aurobindo Pharma Limited has informed the Exchange regarding Disclosure of Related Party Transactions under Reg 23(9) of SEBI (LODR), 2015 for the half year ended March 31, 2019.
April 06, 2018 Disc. under Reg.30 of SEBI (SAST) Reg.2011 Promoter and Promoter Group of the Company has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
See all Announcements

Board Meetings

Date Meeting Date Purpose
May 27, 2020 June 03, 2020 Financial Results To consider and approve the financial results for the period ended March 31, 2020
October 31, 2019 November 12, 2019 Financial Results/Dividend To consider and approve the financial results for the period ended September 30, 2019 and dividend
See all Board Meetings

Get Clearnifty's Android App.

Get clearnifty on Google Play
Get clearnifty on Google Play